The development of Companion Diagnostics (CDx) operates on a powerful and unique paradigm of strategic alliances, creating a symbiotic relationship that is essential for innovation and market success in precision oncology. For large pharmaceutical companies, a targeted therapy cannot gain regulatory approval or achieve commercial success without a high-quality, approved CDx to identify...